An extended release, proprietary mucoadhesive buccal tablet formulation containing the hydrochloride salt form of clonidine, the imidazoline derivative and adrenergic alpha 2 receptor agonist, with anti-inflammatory activity. Upon contact of the tablet with the buccal mucosa, clonidine binds to the adrenergic receptors on macrophages and lymphocytes and may reduce the release of pro-inflammatory mediators such as tumor necrosis factor alpha (TNFalpha). As a result, this agent may prevent chemoradiation therapy-induced mucositis. Check for active clinical trials using this agent. (NCI Thesaurus)
Related Posts
Recent Posts
